BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence

fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a preclinical CD19 autoimmune program.
BMS established itself as a major player in the cell…

This story appeared on fiercebiotech.com, 2025-10-11 21:51:45.585000.
The Entire Business World on a Single Page. Free to Use →